When will the innovative generic price system be improved?

Launch of the PVA Working Group

Operation of PVA public-private working group until November

As announced, the government-pharmaceutical working group for PVA improvement plans started on the 1st with the first meeting and got on track.

 

The industry is complaining of frustration as there is no news about the plan for preferential drug prices for innovative new drugs whose working group has already ended or the reorganization of the generic drug price system that is being pursued together.

 

According to the industry on the 7th, the PVA improvement plan working group will be held from the first meeting on the 1st to November.

 

Originally, this working group was scheduled to run from May to August, but instead of being delayed by one month, the entire period was extended.

 

The government plans to promote institutional improvement next year through a working group.

 

The external research service, which is the basis for the improvement plan of the usage-drug price linkage system, has already been disclosed.

 

The 'PVA Performance Evaluation and Improvement Study' participated by Bae Seung-jin, professor at Ewha Womans University Pharmacy, was also disclosed to the outside world in April.

 

Looking at the main content, in the case of type Ka, currently, only cases where the billing amount increases by 30% or more are included in the negotiation target, but like Na and Da types, a plan to include items with a 10% increase in billing amount & 5 billion won or more presented.

 

It also proposed a plan increase the efficiency of negotiations and system acceptance by raising the exclusion standard from the current claim amount of 2 billion won to 3 to 5 billion won.

 

The core of the study results is to include more expensive drugs with high claims in the PVA negotiation target and to expand the exclusion of low-priced drugs.

 

In the industry, different opinions are expressed depending on the size of the company.

 

Rumor has it that the one-day meeting ended with sharing the results of the research service and simply listening to the opinions of the industry.

 

The NHIS plans to have its staff members travel abroad to France, Japan, and Taiwan to come up with improvement plans.

 

It has already been brought to Taiwan and is known to be planning to visit France and Japan this month.

 

The industry is calmly participating in the fact that the PVA improvement plan has already been disclosed and the operation of the working group was scheduled.

 

Rather, they are looking forward to a meeting to discuss the government's final plan for improving innovative new drugs, which ended in the first half of this year, and plans to improve the generic drug price system.

 

The public-private consultative body to improve innovative new drugs ended after the 5th meeting in March, and the government is waiting for the final draft.

 

The government never met with the industry in a situation where only the media reported that the government was promoting a plan to improve the generic drug price system.

 

Some predict that there will be a face-to-face meeting with the industry after the government plans to prepare an internal draft for improving the generic drug price system by June.

 

An official from the industry said, "This year, not only PVA but also various consultative bodies such as measures to improve the actual transaction price system are scheduled." He said, "The industry is interested in preferential treatment for innovative new drugs and reform of the generic drug price system, but the government's plan is not clear, so the industry is in a frustrating situation."